Answer
The treatments act on complementary growth pathways: endocrine therapy reduces hormone-driven signalling, while ribociclib blocks CDK4/6-mediated cell-cycle progression.
Sources for this answer
- Kisqali film coated tabletsemc · SmPC Current selected SmPC · Version 25
- PubMedPubMed · Reputable Web